Evaluating the Efficacy of Dexamethasone in Treating Tuberculous Meningitis in HIV-Positive Adults
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on October 30th, 2023
|
Tuberculous meningitis poses a significant threat to individuals living with human immunodeficiency virus (HIV), as it is both highly prevalent and life-threatening. Previous research had established the potential clinical benefits of using dexamethasone to mitigate the cerebral inflammation induced by the tuberculosis bacteria. Consequently, a study was undertaken to assess the efficacy of dexamethasone as a treatment for tuberculous meningitis in HIV-positive adults.
The clinical trial involved 520 adult participants who had been diagnosed with both HIV infection and tuberculous meningitis. Notably, approximately half of these participants had not undergone any antiretroviral treatment, and they are in an immunocompromised state of having less than 50 CD4 T-cells per cubic millimeter of blood. These individuals were randomly divided into two groups, with one group receiving a placebo, and the other group receiving dexamethasone. The treatment regimen consisted of an initial intravenous administration over a four-week period, followed by an oral phase lasting four weeks. The specific dosage of dexamethasone varied based on the severity of the tuberculous meningitis, the route of administration, and prior usage. After a 12-month follow-up, the researchers observed that the mortality rate in the group treated with dexamethasone was 44.1%, while the placebo group had a mortality rate of 49.0%. This suggests that the use of dexamethasone did not result in a decreased risk of death attributed to tuberculous meningitis among HIV-positive individuals.
The clinical trial involved 520 adult participants who had been diagnosed with both HIV infection and tuberculous meningitis. Notably, approximately half of these participants had not undergone any antiretroviral treatment, and they are in an immunocompromised state of having less than 50 CD4 T-cells per cubic millimeter of blood. These individuals were randomly divided into two groups, with one group receiving a placebo, and the other group receiving dexamethasone. The treatment regimen consisted of an initial intravenous administration over a four-week period, followed by an oral phase lasting four weeks. The specific dosage of dexamethasone varied based on the severity of the tuberculous meningitis, the route of administration, and prior usage. After a 12-month follow-up, the researchers observed that the mortality rate in the group treated with dexamethasone was 44.1%, while the placebo group had a mortality rate of 49.0%. This suggests that the use of dexamethasone did not result in a decreased risk of death attributed to tuberculous meningitis among HIV-positive individuals.